Trials / Completed
CompletedNCT00401583
A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes
A Multi-center, Open-Label, Multiple-probe Drug Interaction Study to Determine the Effects of GW786034 on the Metabolism of Cytochrome P450 Probe Drugs in Patients With Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I study to determine the effect of GW786034 (pazopanib) on P450 enzymes. This study will help determine which types of drugs may interact with GW786034.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GW786034 (pazopanib) | Pazopanib will be given as monohydrochloride, 100 and 500 mg tablets. |
| DRUG | Probe drugs | probe drugs will be oral midazolam (3 mg), warfarin (10 mg), omeprazole (40 mg), caffeine (200 mg), and dextromethorphan (30 mg). |
Timeline
- Start date
- 2006-07-28
- Primary completion
- 2008-02-20
- Completion
- 2008-02-20
- First posted
- 2006-11-20
- Last updated
- 2017-11-13
Locations
2 sites across 2 countries: United States, Singapore
Source: ClinicalTrials.gov record NCT00401583. Inclusion in this directory is not an endorsement.